Development of a novel vaccine for Zika

The rapid spread of Zika virus worldwide and its association with abnormal fetal brain development has made the need for an effective vaccine clear. Controlling the mosquito vector and protecting people against mosquito bites have been the main means of defending against Zika virus infections.
The viral vector vaccine technology developed by GeoVax uses a highly potent, safe, and replication-deficient viral vector (Modified Vaccinia Ankara, MVA) to express vaccine antigens in the recipient's cells. It has previously been used to develop vaccine candidates for HIV and Ebola virus. The vaccine, from GeoVax Labs, Inc. in Atlanta, Ga., was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, Colo., with funding by a grant from the CDC.
In the presented study, outbred immunocompetent mice were exposed to a lethal challenge dose of Zika virus delivered directly into the brain. "A single dose of GeoVax's NS1 vaccine candidate protected 100% of vaccinated animals," said Guirakhoo. In contrast, 80-90% of sham-immunized control animals died within 7-10 days.
Because the NS1 antigen is not presented on the surface of the virus, it was chosen as the target immunogen for the vaccine to avoid a potential risk of disease enhancement when vaccines are developed based on Zika virus envelope proteins. This "Antibody Dependent Enhancement (ADE) of infection" phenomena has been shown between Zika virus and a related flavivirus, Dengue, in both in vitro and in vivo studies.
An NS1-based vaccine could also limit or block transmission of Zika virus in its mosquito vector. The NS1 protein is abundantly produced by flaviviruses in infected hosts and is picked up together with the virus after the mosquito takes a blood meal from humans. The NS1 proteins interfere with the innate immune system of the mosquito, evolved to fight foreign pathogens, allowing the flavivirus to replicate and disseminate in mosquitoes. Therefore, said Guirakhoo, "a vaccine that can induce effective antibodies to NS1 and disable its function has the potential to reduce growth and transmission of Zika virus in its mosquito vector. This could enhance vaccine effectiveness in endemic areas by blocking the virus transmission from infected individuals to other members of the community."


 for more information visit our product website:Buy Careprost Eye Drops (With Brush) Online
Location: United States

Comments

Post a Comment

Popular posts from this blog

Supportive housing improves health of formerly homeless people with HIV/AIDS

That conclusion seemed clear to Bowen, assistant professor in the University at Buffalo School of Social Work, during the four years she worked in a supportive housing program in Chicago, Illinois. Now as a UB researcher she has published a study that empirically supports what she experienced on the ground. "Supportive housing, a program of rental assistance and support services, is associated with improvements in the health outcomes of previously homeless people living with HIV/AIDS," she says. "Without stable housing it's hard to achieve these good health outcomes." The study, which appears in the journal  AIDS Care , relied on biometric data that predicts how effectively the body combats the virus. Prior to publishing their journal article, the team presented their preliminary findings at the 2016 International AIDS Conference in Durban, South Africa. Bowen and her coauthors examined two indicators of health: CD4 count, sometimes called T-cells, w...
Read more

HIV: A therapeutic advance for resource-limited settings

Second-line treatments of HIV infection recommended by the WHO for resource-limited countries are highly effective. However, there is currently no reliable way of de-escalating these treatments, while maintaining an undetectable viral load. Two strategies may provide a solution. The first is monotherapy with a boosted protease inhibitor (BPI), which in several trials has already yielded encouraging results, albeit with a risk of increased viral load. Such an increase constitutes a risk in resource-limited countries because patients there do not have access to regular virological monitoring, which can identify treatment failure. The second strategy is to combine a BPI with lamivudine, which is inexpensive, well tolerated, often used first line, and effective. This combination, however, has never been evaluated in patients infected by HIV with mutations that confer drug resistance, notably to lamivudine (M184V). ANRS 12286 MOBIDIP is the first trial to compare these two treatment de-e...
Read more

HIV status may affect the progression of HPV infection to cervical pre-cancer

In order to increase understanding of the way HPV infection progresses, and to compare its progression in HIV-negative and HIV-positive women, Whitham and colleagues analyzed data from six studies conducted from 1994 to 2010 in Senegal, where HIV is endemic. They followed 1,320 women for an average of two years, testing them for HPV and cervical abnormalities approximately every four months. At each clinic visit, women were characterized as normal, HPV-positive, or HSIL (HPV-positive with high-grade squamous intraepithelial lesions, a precancerous lesion that may progress to cervical cancer if untreated). The study showed that HIV-positive women had higher rates of acquiring HPV, and lower rates of clearing HPV infection, than HIV-negative women. Women whose immune systems were compromised by HIV were also more likely to have HPV infection progress to pre-cancer, the study indicated. For instance, HIV-positive women were 2.55 times more likely to have their HPV infection progres...
Read more